# hvd medical GmbH Company profile · SME (from the award notice) - Legal form: GmbH - Seat: Saarlouis, Germany Based on the notices and sources Inteliwert covers; not a complete record. Last checked 5 August 2026. ## Identifiers Not found in the indexed notices. ## Track record in public tenders Awards in the covered notices over the last 36 months, per CPV division. | CPV division | Awards | Award value (excl. VAT) | Buyers | Repeat buyers | First award | Last award | | --- | ---: | ---: | ---: | ---: | --- | --- | | 33 Medical equipments, pharmaceuticals and personal care products | 1 | €1 | 1 | 0 | 5 August 2026 | 5 August 2026 | Based on the notices and sources Inteliwert covers; not a complete record. ### Awards - [Abschluss eines nicht-exklusiven Rabattvertrages gemäß § 130c Abs. 1 SGB V zwischen der IKK classic und der hcd medical GmbH zu Vabysmo](https://inteliwert.com/tender/opp_F19BTRB3QMCG90PCCKJK2E3V5B/abschluss-eines-nicht-exklusiven-rabattvertrages-gemaess-130c-abs-1-sgb-v-zwisch) Buyer: IKK classic · Award value: €1 excl. VAT · Awarded: 5 August 2026 · CPV 33600000 ## Certifications and prequalification No certification or prequalification found in the covered sources. A certification missing here is unknown, not absent. ## Website and LinkedIn Not found in the indexed notices. ## Open tenders that might fit *Possible match based on public information* Companies Inteliwert knows from its sources, not the whole market. Inteliwert does not judge eligibility, fit or chances. - [Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Naloxegol, ATC A06AH03 für die Zeit 01.08.2026 - 31.07.2028](https://inteliwert.com/tender/opp_643ZPY4QX2P21AZSD7Z8FZS9M3/abschluss-einer-nicht-exklusiven-rabattvereinbarung-nach-130a-abs-8-sgb-v-zum-wi) Open · SME (from the award notice) · New to public tenders · Buyer: DAK-Gesundheit · Deadline: 5 Jun 2028, 12:00 (UTC+02:00) · [Official notice](https://oeffentlichevergabe.de/ui/de/notices/7f775bda-6bfe-4cac-a55f-22d1c7aa1799), Last checked 11 Nov 2026, 19:31 (UTC+01:00) - Won a contract in CPV group 336 (2026-08-05): [Evidence](https://inteliwert.com/tender/opp_F19BTRB3QMCG90PCCKJK2E3V5B/abschluss-eines-nicht-exklusiven-rabattvertrages-gemaess-130c-abs-1-sgb-v-zwisch), checked 12 Nov 2026 - The contract value is close to the values of its past awards: [Evidence](https://inteliwert.com/tender/opp_643ZPY4QX2P21AZSD7Z8FZS9M3/abschluss-einer-nicht-exklusiven-rabattvereinbarung-nach-130a-abs-8-sgb-v-zum-wi), checked 11 Nov 2026 - 1 award in this field in 36 months, from 1 buyer: [Evidence](https://inteliwert.com/tender/opp_F19BTRB3QMCG90PCCKJK2E3V5B/abschluss-eines-nicht-exklusiven-rabattvertrages-gemaess-130c-abs-1-sgb-v-zwisch), checked 12 Nov 2026 - [Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Peginterferon alfa-2a, ATC L03AB11 für die Zeit 01.08.2026 - 31.07.2028](https://inteliwert.com/tender/opp_1G1TJQ869PT3MF5ZS69VH8E72Q/abschluss-einer-nicht-exklusiven-rabattvereinbarung-nach-130a-abs-8-sgb-v-zum-wi) Open · SME (from the award notice) · New to public tenders · Buyer: DAK-Gesundheit · Deadline: 5 Jun 2028, 12:00 (UTC+02:00) · [Official notice](https://oeffentlichevergabe.de/ui/de/notices/4f16a9cb-ad8b-4b30-afb0-420423ea53cb), Last checked 11 Nov 2026, 19:31 (UTC+01:00) - Won a contract in CPV group 336 (2026-08-05): [Evidence](https://inteliwert.com/tender/opp_F19BTRB3QMCG90PCCKJK2E3V5B/abschluss-eines-nicht-exklusiven-rabattvertrages-gemaess-130c-abs-1-sgb-v-zwisch), checked 12 Nov 2026 - The contract value is close to the values of its past awards: [Evidence](https://inteliwert.com/tender/opp_1G1TJQ869PT3MF5ZS69VH8E72Q/abschluss-einer-nicht-exklusiven-rabattvereinbarung-nach-130a-abs-8-sgb-v-zum-wi), checked 11 Nov 2026 - 1 award in this field in 36 months, from 1 buyer: [Evidence](https://inteliwert.com/tender/opp_F19BTRB3QMCG90PCCKJK2E3V5B/abschluss-eines-nicht-exklusiven-rabattvertrages-gemaess-130c-abs-1-sgb-v-zwisch), checked 12 Nov 2026 - [Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Budesonid (FAM Kinpeygo und austauschbare Arzneimittel), ATC A07EA06 für die Zeit 01.08.2026 - 31.07.2028](https://inteliwert.com/tender/opp_0GMBMKG62TQV8JCM10TTPZEPSP/abschluss-einer-nicht-exklusiven-rabattvereinbarung-nach-130a-abs-8-sgb-v-zum-wi) Open · SME (from the award notice) · New to public tenders · Buyer: DAK-Gesundheit · Deadline: 5 Jun 2028, 12:00 (UTC+02:00) · [Official notice](https://oeffentlichevergabe.de/ui/de/notices/deba4f56-6454-41e8-a5a9-5ac3fe5c520a), Last checked 11 Nov 2026, 19:31 (UTC+01:00) - Won a contract in CPV group 336 (2026-08-05): [Evidence](https://inteliwert.com/tender/opp_F19BTRB3QMCG90PCCKJK2E3V5B/abschluss-eines-nicht-exklusiven-rabattvertrages-gemaess-130c-abs-1-sgb-v-zwisch), checked 12 Nov 2026 - The contract value is close to the values of its past awards: [Evidence](https://inteliwert.com/tender/opp_0GMBMKG62TQV8JCM10TTPZEPSP/abschluss-einer-nicht-exklusiven-rabattvereinbarung-nach-130a-abs-8-sgb-v-zum-wi), checked 11 Nov 2026 - 1 award in this field in 36 months, from 1 buyer: [Evidence](https://inteliwert.com/tender/opp_F19BTRB3QMCG90PCCKJK2E3V5B/abschluss-eines-nicht-exklusiven-rabattvertrages-gemaess-130c-abs-1-sgb-v-zwisch), checked 12 Nov 2026 - [Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Omalizumab, ATC L04AG08 für die Zeit 01.08.2026 - 31.07.2028](https://inteliwert.com/tender/opp_R69AQ178WP7B2E36XM6GM9916W/abschluss-einer-nicht-exklusiven-rabattvereinbarung-nach-130a-abs-8-sgb-v-zum-wi) Open · SME (from the award notice) · New to public tenders · Buyer: DAK-Gesundheit · Deadline: 5 Jun 2028, 12:00 (UTC+02:00) · [Official notice](https://oeffentlichevergabe.de/ui/de/notices/4d0745e1-4dce-449c-a39d-6352edce83d4), Last checked 11 Nov 2026, 19:31 (UTC+01:00) - Won a contract in CPV group 336 (2026-08-05): [Evidence](https://inteliwert.com/tender/opp_F19BTRB3QMCG90PCCKJK2E3V5B/abschluss-eines-nicht-exklusiven-rabattvertrages-gemaess-130c-abs-1-sgb-v-zwisch), checked 12 Nov 2026 - The contract value is close to the values of its past awards: [Evidence](https://inteliwert.com/tender/opp_R69AQ178WP7B2E36XM6GM9916W/abschluss-einer-nicht-exklusiven-rabattvereinbarung-nach-130a-abs-8-sgb-v-zum-wi), checked 11 Nov 2026 - 1 award in this field in 36 months, from 1 buyer: [Evidence](https://inteliwert.com/tender/opp_F19BTRB3QMCG90PCCKJK2E3V5B/abschluss-eines-nicht-exklusiven-rabattvertrages-gemaess-130c-abs-1-sgb-v-zwisch), checked 12 Nov 2026 - [Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Tocilizumab (ausschließlich Darreichungsform PEN und FER), ATC L04AC07 für die Zeit 01.08.2026 - 31.07.2028](https://inteliwert.com/tender/opp_E5XX4YBKC8DTZAA3XVMYZ7X2E9/abschluss-einer-nicht-exklusiven-rabattvereinbarung-nach-130a-abs-8-sgb-v-zum-wi) Open · SME (from the award notice) · New to public tenders · Buyer: DAK-Gesundheit · Deadline: 5 Jun 2028, 12:00 (UTC+02:00) · [Official notice](https://oeffentlichevergabe.de/ui/de/notices/a2d0879e-fd75-48a8-b97b-fe6de61f0645), Last checked 11 Nov 2026, 19:31 (UTC+01:00) - Won a contract in CPV group 336 (2026-08-05): [Evidence](https://inteliwert.com/tender/opp_F19BTRB3QMCG90PCCKJK2E3V5B/abschluss-eines-nicht-exklusiven-rabattvertrages-gemaess-130c-abs-1-sgb-v-zwisch), checked 12 Nov 2026 - The contract value is close to the values of its past awards: [Evidence](https://inteliwert.com/tender/opp_E5XX4YBKC8DTZAA3XVMYZ7X2E9/abschluss-einer-nicht-exklusiven-rabattvereinbarung-nach-130a-abs-8-sgb-v-zum-wi), checked 11 Nov 2026 - 1 award in this field in 36 months, from 1 buyer: [Evidence](https://inteliwert.com/tender/opp_F19BTRB3QMCG90PCCKJK2E3V5B/abschluss-eines-nicht-exklusiven-rabattvertrages-gemaess-130c-abs-1-sgb-v-zwisch), checked 12 Nov 2026 - [Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Ranibizumab, ATC S01LA04 für die Zeit 01.09.2026 - 31.08.2028](https://inteliwert.com/tender/opp_H0QGRZ7FN4SBYJSJ5W4ZR3M9SC/abschluss-einer-nicht-exklusiven-rabattvereinbarung-nach-130a-abs-8-sgb-v-zum-wi) Open · SME (from the award notice) · New to public tenders · Buyer: DAK-Gesundheit · Deadline: 5 Jul 2028, 12:00 (UTC+02:00) · [Official notice](https://oeffentlichevergabe.de/ui/de/notices/ebd393d3-9d1b-4561-a759-4035c4996870), Last checked 10 Nov 2026, 10:30 (UTC+01:00) - Won a contract in CPV group 336 (2026-08-05): [Evidence](https://inteliwert.com/tender/opp_F19BTRB3QMCG90PCCKJK2E3V5B/abschluss-eines-nicht-exklusiven-rabattvertrages-gemaess-130c-abs-1-sgb-v-zwisch), checked 10 Nov 2026 - The contract value is close to the values of its past awards: [Evidence](https://inteliwert.com/tender/opp_H0QGRZ7FN4SBYJSJ5W4ZR3M9SC/abschluss-einer-nicht-exklusiven-rabattvereinbarung-nach-130a-abs-8-sgb-v-zum-wi), checked 10 Nov 2026 - 1 award in this field in 36 months, from 1 buyer: [Evidence](https://inteliwert.com/tender/opp_F19BTRB3QMCG90PCCKJK2E3V5B/abschluss-eines-nicht-exklusiven-rabattvertrages-gemaess-130c-abs-1-sgb-v-zwisch), checked 10 Nov 2026 - [Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Abatacept, ATC L04AA24 für die Zeit 01.09.2026 - 31.08.2028](https://inteliwert.com/tender/opp_R84WBD019P23ZWQMYWAFC54C8B/abschluss-einer-nicht-exklusiven-rabattvereinbarung-nach-130a-abs-8-sgb-v-zum-wi) Open · SME (from the award notice) · New to public tenders · Buyer: DAK-Gesundheit · Deadline: 5 Jul 2028, 12:00 (UTC+02:00) · [Official notice](https://oeffentlichevergabe.de/ui/de/notices/b5ad4b99-f341-4a31-a232-b6328a787e51), Last checked 10 Nov 2026, 10:30 (UTC+01:00) - Won a contract in CPV group 336 (2026-08-05): [Evidence](https://inteliwert.com/tender/opp_F19BTRB3QMCG90PCCKJK2E3V5B/abschluss-eines-nicht-exklusiven-rabattvertrages-gemaess-130c-abs-1-sgb-v-zwisch), checked 10 Nov 2026 - The contract value is close to the values of its past awards: [Evidence](https://inteliwert.com/tender/opp_R84WBD019P23ZWQMYWAFC54C8B/abschluss-einer-nicht-exklusiven-rabattvereinbarung-nach-130a-abs-8-sgb-v-zum-wi), checked 10 Nov 2026 - 1 award in this field in 36 months, from 1 buyer: [Evidence](https://inteliwert.com/tender/opp_F19BTRB3QMCG90PCCKJK2E3V5B/abschluss-eines-nicht-exklusiven-rabattvertrages-gemaess-130c-abs-1-sgb-v-zwisch), checked 10 Nov 2026 - [Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Brolucizumab, ATC S01LA06 für die Zeit 01.09.2026 - 31.08.2028](https://inteliwert.com/tender/opp_AJR92HYNZK0KM4JVGS6NHHM53D/abschluss-einer-nicht-exklusiven-rabattvereinbarung-nach-130a-abs-8-sgb-v-zum-wi) Open · SME (from the award notice) · New to public tenders · Buyer: DAK-Gesundheit · Deadline: 5 Jul 2028, 12:00 (UTC+02:00) · [Official notice](https://oeffentlichevergabe.de/ui/de/notices/2c2351ca-f10a-4a62-b527-2a364eb86a7a), Last checked 10 Nov 2026, 10:30 (UTC+01:00) - Won a contract in CPV group 336 (2026-08-05): [Evidence](https://inteliwert.com/tender/opp_F19BTRB3QMCG90PCCKJK2E3V5B/abschluss-eines-nicht-exklusiven-rabattvertrages-gemaess-130c-abs-1-sgb-v-zwisch), checked 10 Nov 2026 - The contract value is close to the values of its past awards: [Evidence](https://inteliwert.com/tender/opp_AJR92HYNZK0KM4JVGS6NHHM53D/abschluss-einer-nicht-exklusiven-rabattvereinbarung-nach-130a-abs-8-sgb-v-zum-wi), checked 10 Nov 2026 - 1 award in this field in 36 months, from 1 buyer: [Evidence](https://inteliwert.com/tender/opp_F19BTRB3QMCG90PCCKJK2E3V5B/abschluss-eines-nicht-exklusiven-rabattvertrages-gemaess-130c-abs-1-sgb-v-zwisch), checked 10 Nov 2026 - [Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Umeclidinium + Vilanterol, ATC R03AL03 für die Zeit 01.09.2026 - 31.08.2028](https://inteliwert.com/tender/opp_4PNRYRMGQCN08VYKVBYS2E39MW/abschluss-einer-nicht-exklusiven-rabattvereinbarung-nach-130a-abs-8-sgb-v-zum-wi) Open · SME (from the award notice) · New to public tenders · Buyer: DAK-Gesundheit · Deadline: 5 Jul 2028, 12:00 (UTC+02:00) · [Official notice](https://oeffentlichevergabe.de/ui/de/notices/4594db64-ac50-4966-acf4-cc9ad5e28970), Last checked 10 Nov 2026, 10:30 (UTC+01:00) - Won a contract in CPV group 336 (2026-08-05): [Evidence](https://inteliwert.com/tender/opp_F19BTRB3QMCG90PCCKJK2E3V5B/abschluss-eines-nicht-exklusiven-rabattvertrages-gemaess-130c-abs-1-sgb-v-zwisch), checked 10 Nov 2026 - The contract value is close to the values of its past awards: [Evidence](https://inteliwert.com/tender/opp_4PNRYRMGQCN08VYKVBYS2E39MW/abschluss-einer-nicht-exklusiven-rabattvereinbarung-nach-130a-abs-8-sgb-v-zum-wi), checked 10 Nov 2026 - 1 award in this field in 36 months, from 1 buyer: [Evidence](https://inteliwert.com/tender/opp_F19BTRB3QMCG90PCCKJK2E3V5B/abschluss-eines-nicht-exklusiven-rabattvertrages-gemaess-130c-abs-1-sgb-v-zwisch), checked 10 Nov 2026 - [Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Triptorelin, ATC L02AE04 für die Zeit 01.09.2026 - 31.08.2028](https://inteliwert.com/tender/opp_PG2YE8Y0MT443WCZ0S0DTV2X3E/abschluss-einer-nicht-exklusiven-rabattvereinbarung-nach-130a-abs-8-sgb-v-zum-wi) Open · SME (from the award notice) · New to public tenders · Buyer: DAK-Gesundheit · Deadline: 5 Jul 2028, 12:00 (UTC+02:00) · [Official notice](https://oeffentlichevergabe.de/ui/de/notices/f4ada9c2-67ab-4af0-b35a-636c62d869b1), Last checked 10 Nov 2026, 10:30 (UTC+01:00) - Won a contract in CPV group 336 (2026-08-05): [Evidence](https://inteliwert.com/tender/opp_F19BTRB3QMCG90PCCKJK2E3V5B/abschluss-eines-nicht-exklusiven-rabattvertrages-gemaess-130c-abs-1-sgb-v-zwisch), checked 10 Nov 2026 - The contract value is close to the values of its past awards: [Evidence](https://inteliwert.com/tender/opp_PG2YE8Y0MT443WCZ0S0DTV2X3E/abschluss-einer-nicht-exklusiven-rabattvereinbarung-nach-130a-abs-8-sgb-v-zum-wi), checked 10 Nov 2026 - 1 award in this field in 36 months, from 1 buyer: [Evidence](https://inteliwert.com/tender/opp_F19BTRB3QMCG90PCCKJK2E3V5B/abschluss-eines-nicht-exklusiven-rabattvertrages-gemaess-130c-abs-1-sgb-v-zwisch), checked 10 Nov 2026 ## Is this your company? Send corrections, or ask us to remove the profile, to . You can also ask that the company never be tagged on LinkedIn. ## About this profile Each fact on this page shows its source: a public notice, an open-data register (GLEIF, Wikidata) or the company’s own website. Inteliwert does not rate companies and does not judge eligibility, fit or chances. **Based on the notices and sources Inteliwert covers; not a complete record.** Last checked 5 August 2026. --- Page: https://inteliwert.com/company/org_CZ8DSXNMY2CMXEKPKR23JR6434/hvd-medical-gmbh Inteliwert is a product of Bandpey GmbH, an international data and AI software company in Munich, Germany, founded and led by Roozbeh Bandpey. Bandpey's products: Facthory, Emolysis, Copolly and Inteliwert. Inteliwert on LinkedIn: https://www.linkedin.com/company/intelliwert, GitHub: https://github.com/inteliwertai.